These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 17128529)

  • 21. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
    Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I
    Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
    Pérez Velasco R
    J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
    Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
    Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
    Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
    Ho P; Sherman P; Grigg A
    Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
    Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
    Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
    Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma.
    Engert A; del Giglio A; Bias P; Lubenau H; Gatzemeier U; Heigener D
    Onkologie; 2009 Oct; 32(10):599-604. PubMed ID: 19816079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
    Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L
    Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing the management of chemotherapy-induced neutropenia.
    Dale DC
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.